Navigation Links
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Date:8/29/2010

nts a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that Sanofi-Aventis had made an approach to acquire Genzyme.  Based on the analysts' consensus estimates, this represents a multiple of 36 times 2010 EPS and 20 times 2011 EPS, which takes into account the expected recovery of Genzyme's performance in 2011.

We believe that now is the right time for you and the Genzyme Board to consider a potential transaction that maximizes value for Genzyme's shareholders.  Genzyme has underperformed its peers for a number of years.  It continues to face several significant and well-documented challenges that were discussed thoroughly during this year's proxy campaign, and which Genzyme recently disclosed will take three to four years to resolve.  An acquisition by Sanofi-Aventis would not only position Genzyme to overcome these challenges quickly and successfully by applying Sanofi-Aventis' global resources and expertise to help realize Genzyme's business strategy, but also deliver near-term compelling value to Genzyme's shareholders that takes into account the company's future upside potential.

As I explained in my July 29 letter, the proposed transaction would provide several key benefits to Genzyme, its shareholders, employees and the patients and physicians it serves, including:

  • Achievement of Genzyme's Vision:  Sanofi-Aventis would put its full resources behind Genzyme to invest in developing new treatments, enhance penetration in existing markets and further expand into emerging markets.  Genzyme would be able to leverage Sanofi-Aventis' strong global footprint and its manufacturing expertise in order to address Genzyme's manufacturing issues.

  • Center of Excellence:  Sanofi-Aventis already recognizes the strategic importance of the greater Boston area as evidenced by the establishment of Sanofi-Aventis'
    '/>"/>

  • SOURCE Sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    3. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
    4. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
    5. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
    6. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
    7. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
    8. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
    9. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
    10. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    11. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, ... devoted to bringing new products to market, has ... called TetraStem. TetraStem is a topical liquid tetracycline-based ... system that can convert oral medication active ingredients ... as a first aid antibiotic to help prevent ...
    (Date:10/30/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Wednesday, November 5, 2014 ... management will hold a conference call at 7:30 a.m. ... 8:30 p.m., Beijing Time on November 6, 2014, to ...
    (Date:10/30/2014)... MADRID , October 30, 2014 ... hidrolizada con probiótico LGG contribuye a adquirir tolerancia ... La alergia a la proteína de la leche ... lactantes y primera infancia. Hasta ahora, la APLV ... dieta. Recientemente, se ha demostrado que es posible ...
    Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
    ... of data from more than 12,000 people with cystic fibrosis ... infection in the Cystic Fibrosis Foundation,s Patient Registry shows that ... associated with a 21% reduction in mortality in the following ... North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, sponsored ...
    ... Bionovo, Inc. (Nasdaq: BNVI ) today announced ... discussing new classes of estrogen receptor modulating drugs with ... in the most recent edition of Current Opinion ... Specific Target Genes and Biological Responses by Estrogen Receptor ...
    Cached Medicine Technology:Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 2Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 3Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 4Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 5Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 2Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 3Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 4
    (Date:10/30/2014)... have to be at least 2 years old to ... no official U.S. guidance exists other than the general ... breastfeed for at least the first six months. , ... That,s the question that motivated researchers at the University ... study the eating patterns of American infants at 6 ...
    (Date:10/30/2014)... 2014 Nutrition Leaders, a popular online ... aids, and more, is currently hosting a sweepstakes on ... underway, is open to U.S. residents age 18 and ... 2014. One lucky winner will then be selected at ... gift card to NutritionLeaders.com. , Nutrition Leaders’ managing director ...
    (Date:10/30/2014)... Burlington, NC (PRWEB) October 30, 2014 ... life, commercial, and health insurance plans for North Carolina ... its satellite office in Burlington’s Holly Hill Mall. The ... 15, with agents already helping customers through all facets ... policy purchase. , Allred Insurance spokesman Scott Allred couldn’t ...
    (Date:10/30/2014)... PreDiabetes Centers , the pioneer in prediabetes ... a supply of sugardown®, a chewable dietary supplement that ... spikes. Learning how to control blood sugar levels and ... diabetes prevention plan. , Shoppers who spend $50 or ... sugardown. The offer expires November 30. , Full-size ...
    (Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
    Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
    ... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
    ... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
    ... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
    ... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
    ... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
    ... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
    Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
    ... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
    SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
    ... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
    ... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
    Medicine Products: